Prof. Reuven Or, MD

Professor of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Director, Department of Bone Marrow Transplantation and Cancer Immunotherapy.

Medical manager, Israel Bone Marrow Donors Registry and The Umbilical Cord Blood Bank

Professor Or is a pioneer in bone marrow transplant procedures. His team was one of the first to discover bone marrow transplantation’s efficacy was due to an effective immune response of the donor immune cells against host tumors, rather than due to the chemotherapy conditioning found that these transplanted immune cells were able to eliminate the last tumor cells from the body of the transplant recipient more effectively than toxic reagents. Prof. Or believes, based on his experience, that immunotherapy has the best potential to cure cancer, better than radiation and chemotherapy.


Dr. Richard Goldberg, MD

Physician-in-Chief, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Richard J. Solove Institute

Klotz Family Chair of Cancer Research

Professor, Internal Medicine, College of Medicine

Associate Director of Outreach, OSU Comprehensive Cancer Center

Chair and CEO for ARCAD US Foundation

Co-Chair, Society for Translational Medicine

Dr. Goldberg is an internationally renowned gastrointestinal oncologist named as one of America’s Best Doctors. He has been listed in U.S.News and World Report’s Top Doctors for multiple consecutive years. He has also been listed in Who’s Who in Medical Sciences Education and in Best Doctors since 2001. He leads a medical staff of more than 100 surgical, medical and radiation oncologists, each specializing in gastrointestinal cancer and working as part of a multidisciplinary clinical team. Goldberg came to Ohio State in 2012. Prior to that he was at the University of North Carolina at Chapel Hill, where he was a distinguished professor of gastrointestinal cancer research and the physician-in-chief at North Carolina Cancer Hospital. He is also the chair and CEO for ARCAD US Foundation and the co-chair of the Society of Translational Oncology.


Dr. Scott Waldman, MD/PhD

Vice President, Clinical and Translational Research, Thomas Jefferson University Associate Dean, Clinical and Translational Sciences, Jefferson Medical College Chair, Department of Pharmacology and Experimental Therapeutics Samuel MV Hamilton Endowed Professor Director, GI Malignancies Program, Kimmel Cancer Center

Dr. Waldman is a clinical scientist with expertise in immunotherapy and translational medicine. He serves as a member of the National Cancer Institute’s Initial Review Group on grant proposals and clinical trial designs and also serves as a member of the Expert Panel on Pharmacology and Therapeutics, Pediatric Pharmacology Research Unit (PPRU) Network, National Institute of Child Health and Human Development. His laboratory is a leading center for discovery and translation to the clinic of new experimental therapeutics. He studies the molecular mechanisms regulating guanylyl cyclases and the regulation of the cell cycle, differentiation, metabolic programming and DNA damage and repair, transcription factors mediating tissue-specific expression of protein and molecular markers of cancer, Dr Waldman has written and lectured about the prospects for using immunotherapy methods to treat colorectal cancer.


Dr. Cathy Eng, MD

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Medical Director, Colorectal Center

Director of Network Clinical Research, GI Medical Oncology

Co-Chair,  SWOG Rectal Subcommittee

The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention.  Dr. Eng heads the MD Anderson GI Department. She is a world renowned clinician and clinical researcher in colorectal cancer. Dr. Eng has been the principle investigator on all recent new drug developments in colorectal cancer, leading the field in establishing the standard of care for this disease which is followed by clinicians all over the world. 



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more